PTC518, Novartis and Huntington's disease

Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Divi's Laboratories Ltd's shares were trading nearly 3% lower on December 5 as Novartis failed to persuade a US appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis ...
HSBC analyst Rajesh Kumar downgraded Novartis (NVS) to Reduce from Hold with a price target of CHF 82, down from CHF 95. The firm calls the ...
Novartis has announced the acquisition of San Diego-based Kate Therapeutics in a deal valued at $1.1bn, enhancing its ...
Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...
Fmr LLC grew its position in shares of Novartis AG (NYSE:NVS – Free Report) by 5.5% during the 3rd quarter, Holdings ...